Journal article
Effect of sorafenib (S) starting dose and dose intensity on survival in patients with hepatocellular carcinoma (HCC): Results from a Canadian multicenter HCC database.
Abstract
4084
Background: The SHARP trial showed that S improves survival in advanced HCC. Full dose (FD) S at 400mg bid can be difficult to tolerate, so some clinicians begin with a reduced dose (RD) & escalate as tolerated to maximum dose. The purpose of this study was to determine whether starting dose or dose intensity of S affects survival. Methods: All patients treated with S for HCC from 01/2008 to 06/2016 in British Columbia, …
Authors
Alghamdi MA; Lee-Ying R; Sim H-W; Samawi H; Knox JJ; Romagnino A; Ko Y-J; Chan KK; Swiha M; Batuyong E
Journal
Journal of Clinical Oncology, Vol. 35, No. 15_suppl, pp. 4084–4084
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2017
DOI
10.1200/jco.2017.35.15_suppl.4084
ISSN
0732-183X